300497.SZ
Jiangxi Fushine Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 17.02
−1.45%Sep 18, 2026, 08:16 UTC
Fuxiang Co., Ltd. announced preliminary guidance for the first three quarters of 2026, expecting net profit attributable to shareholders of RMB 350-430 million, turning profitable year-on-year from a loss of RMB 62.7515 million, driven by higher volumes and prices of new-energy lithium battery electrolyte additive products.
Aug 13, 2026, 17:40 UTC
Fuxiang Co., Ltd. reported H1 2026 revenue of 888 million yuan, up 72.59% year-on-year, and net profit of 177 million yuan, turning from loss to profit, driven by price increases and capacity expansion in electrolyte additives.
Source:Aug 11, 2026, 10:43 UTC
Fuxiang Co., Ltd. announced an interim dividend for the first half of 2026 of 0.5 yuan per 10 shares, totaling 26.93 million yuan, approved by the board on August 10.
Source:Aug 2, 2026, 08:11 UTC
Fuxiang Co., Ltd. signed a guarantee contract with Bank of Communications Jingdezhen Branch in 2026, providing a maximum guarantee of RMB 150 million for its wholly-owned subsidiary Fuxiang Technology, with the guarantee period from July 30, 2026 to January 30, 2028.
Source:Jul 23, 2026, 07:59 UTC
Fushun Co., Ltd.'s chairman proposed a 2026 interim dividend plan of 0.5 yuan per 10 shares.
Source: